Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Email this article to a Colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to My Articles & Searches Download to citation manager Citing Articles via HighWire Citing Articles via Google Scholar Articles by Thieda, P. Articles by Kane, J. Search for Related Content PubMed Citation Articles by Thieda, P. Articles by Kane, J. Treatment Compliance Costs, Cost Analysis Schizophrenia Spectrum Disorders

An Economic Review of Compliance With Medication Therapy in the Treatment of Schizophrenia

OBJECTIVES: The authors examined published economic evaluations of schizophrenia and antipsychotic therapies to determine the role of compliance with medication therapy in the economic cost of schizophrenia. METHODS: The authors reviewed studies published from 1995 to 2002 that evaluated compliance with treatment for schizophrenia. Literature searches were conducted for that period by using MEDLINE, EMBASE, and Current Contents. The primary search terms were "schizophrenia," "compliance," "relapse," and "economic costs." RESULTS AND CONCLUSIONS: A definitive relationship exists between compliance and the economic costs of schizophrenia. Lower rates of compliance lead to higher costs of treating schizophrenia. However, the full implications are difficult to surmise from the literature because of inadequacies in the reporting of compliance rates and outcomes of treatment over time. The authors suggest collection of data on longer-term clinical outcomes as a means to improve future economic evaluations of schizophrenia treatments.

This article has been cited by other articles:

				R.A. Rosenheck, D.L. Leslie, S. Busch, E. S. Rofman, and M. Sernyak Rethinking Antipsychotic Formulary Policy Schizophr Bull, March 1, 2008; 34(2): 375 - 380. [Abstract] [Full Text] [PDF]

				A. C. Singh, A. J. Massey, M. D. Thompson, L. R. Rappa, and M. S. Honeywell Addressing Nonadherence in the Schizophrenic Population Journal of Pharmacy Practice, December 1, 2006; 19(6): 361 - 368. [Abstract] [PDF]

				M. S Turner and D. W Stewart Review of the evidence for the long-term efficacy of atypical antipsychotic agents in the treatment of patients with schizophrenia and related psychoses. J Psychopharmacol, November 1, 2006; 20(6 Suppl): 20 - 37. [Abstract] [PDF]

				M. T. Compton, B. E. Rudisch, J. Craw, T. Thompson, and D. A. Owens Predictors of Missed First Appointments at Community Mental Health Centers After Psychiatric Hospitalization Psychiatr Serv, April 1, 2006; 57(4): 531 - 537. [Abstract] [Full Text] [PDF]

				D. L. Penn, E. J. Waldheter, D. O. Perkins, K. T. Mueser, and J. A. Lieberman Psychosocial Treatment for First-Episode Psychosis: A Research Update Am J Psychiatry, December 1, 2005; 162(12): 2220 - 2220. [Abstract] [Full Text] [PDF]

				W. Kissling, S. Heres, K. Lloyd, E. Sacchetti, P. Bouhours, R. Medori, and P. M. Llorca Direct transition to long-acting risperidone - analysis of long-term efficacy J Psychopharmacol, September 1, 2005; 19(5_suppl): 15 - 21. [Abstract] [PDF]

Get information about faster international access.

Privacy Policy

Copyright © 2003 American Psychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us